| CDK4/6i | CDK4/6 inhibitors |
| ET | Endocrine therapy |
| DRFS | Distant recurrence-free survival |
| iDFS | Invasive disease-free survival |
| OS | Overall survival |
| HR+ | Hormone Receptor-positive |
| HER2− | Human Epidermal Growth Factor 2-negative |
| RCTs | Randomized controlled trials |
| CDKs | Cyclin-dependent kinases |
| ER+ | Estrogen receptor positive |
| Rb | Retinoblastoma protein |
| a/mBC | Advanced or metastatic breast cancer |
| PFS | Progression-free survival |
| ABC | Advanced breast cancer |
| DFS | Disease-free survival |
| HR | Hazard ratios |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.